PharmaLex appoints Dr Adam King to its regulatory team

PharmaLex has appointed Dr Adam King as its senior director, regulatory affairs and service area, a role that will see him work on regulatory activities related to mergers and acquisitions.

He brings over 30 years’ experience working in the pharmaceutical industry to the Mannheim, Germany-based pharmaceutical services group. During that time he spent over 18 years in regulatory affairs, with a focus on radiopharmaceuticals, regulatory strategy development and the oversight of regulatory affairs CMC programmes.

He said: “I am excited to be part of the PharmaLex team and to spearhead a delivery service area to offer my experience for current/prospective clients in supporting the regulatory activities related to mergers and acquisitions.”

King’s most recent experiences include leading a team of regulatory consultants to complete a CMC compliance project and he has also been R&D lead for the design and implementation of an electronic document management system, publishing tools into a combined R&D and manufacturing environment.

Dr Kirsten Jacobs, executive vice president, head of global regulatory affairs at PharmaLex, said: “Adam’s appointment demonstrates our commitment to developing our existing regulatory team, helping to guide our growing customer base to regulatory milestone achievements.

“His wide-ranging experience of activities needed for M&A will provide both the UK and global team with vital skills that enable us to provide our clients with added value.”